A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
Clinical trial NCT07709494 · RECRUITING
Trial details
- NCT number
- NCT07709494
- Sponsor
- Revagenix, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-13
- Primary completion
- 2027-06-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.